Bottom line
How much do PHSYX and LHCOX overlap?
52% of their top holdings overlap by weight. 10 securities appear in both funds' top 25, making up 53.0% of PHSYX's assets and 40.1% of LHCOX's. They share a meaningful core but differ in the rest of the portfolio.
Updated Nov 22, 2026
Overlap at a glance
Holdings PHSYX and LHCOX have in common
| Holding | % of PHSYX | % of LHCOX | Overlap |
|---|---|---|---|
| Eli Lilly & Co. | 13.15% | 10.40% | 10.40% |
| Johnson & Johnson | 8.46% | 4.96% | 4.96% |
| UnitedHealth Group, Inc. | 6.93% | 5.39% | 5.39% |
| Novartis AG | 5.13% | 4.19% | 4.19% |
| AstraZeneca plc | 4.67% | 1.97% | 1.97% |
| Thermo Fisher Scientific, Inc. | 4.50% | 2.31% | 2.31% |
| Edwards Lifesciences Corp. | 2.80% | 1.78% | 1.78% |
| CVS Health Corp. | 2.74% | 3.33% | 2.74% |
| Gilead Sciences, Inc. | 2.63% | 3.53% | 2.63% |
| Vertex Pharmaceuticals, Inc. | 1.97% | 2.24% | 1.97% |
Source: SEC Form N-PORT (periods May 31, 2026 / Jul 31, 2026)
Free weekly newsletter
The Fund Letter
Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.
Free. Unsubscribe anytime. We never sell your email.
What each fund holds that the other doesn't
Top-25 holdings that appear in only one of the two funds' top 25.
Only in PHSYX
- AbbVie, Inc. — 6.05%
- Merck & Co., Inc. — 4.88%
- Intuitive Surgical, Inc. — 4.04%
- Sanofi SA — 3.23%
- Roche Holding AG — 2.79%
- McKesson Corp. — 2.14%
- Cardinal Health, Inc. — 2.12%
- Novo Nordisk A/S — 1.90%
- Boston Scientific Corp. — 1.80%
- Bristol-Myers Squibb Co. — 1.75%
- Dexcom, Inc. — 1.64%
- Hoya Corp. — 1.52%
- Putnam Short Term Investment Fund — 1.35%
- HCA Healthcare, Inc. — 1.18%
- Amgen, Inc. — 1.11%
Only in LHCOX
- Natera Inc — 3.60%
- Guardant Health Inc — 2.61%
- Galderma Group AG — 2.60%
- Cogent Biosciences Inc — 2.27%
- 10X Genomics Inc — 2.16%
- BeOne Medicines Ltd — 2.06%
- Ascendis Pharma A/S — 1.99%
- Madrigal Pharmaceuticals Inc — 1.91%
- Bridgebio Pharma Inc — 1.84%
- Revolution Medicines Inc — 1.67%
- Arrowhead Pharmaceuticals Inc — 1.52%
- Protagonist Therapeutics Inc — 1.44%
- Dianthus Therapeutics Inc — 1.44%
- Adaptive Biotechnologies Corp — 1.42%
- Illumina Inc — 1.42%
Asset mix
| Asset type | PHSYX | LHCOX |
|---|---|---|
| Stocks | 98.2% | 98.2% |
| Other | 1.4% | — |
| Repurchase agreements | — | 1.2% |
| Cash & short-term funds | 0.6% | 0.8% |
Source: SEC Form N-PORT (periods May 31, 2026 / Jul 31, 2026)
Country mix
| Country | PHSYX | LHCOX |
|---|---|---|
| US | 76.2% | 78.5% |
| CH | 7.9% | 8.8% |
| GB | 6.4% | 2.0% |
| FR | 3.2% | 0.5% |
| DK | 2.4% | 2.0% |
| JP | 2.4% | 1.2% |
| NL | 1.2% | 2.2% |
| BE | — | 1.4% |
Source: SEC Form N-PORT (periods May 31, 2026 / Jul 31, 2026)
Check another pair
FAQ
How much do PHSYX and LHCOX overlap?
What stocks do PHSYX and LHCOX have in common?
Should I own both PHSYX and LHCOX?
Which holds more stocks, PHSYX or LHCOX?
Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.